These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 28699311)

  • 21. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resource Use and Financial Impact of Oral Step-Down Therapy for Resistant Cytomegalovirus in Solid Organ Transplant Recipients.
    Kleiboeker H; Descourouez JL; Schulz LT; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA; Jorgenson MR
    Transplant Proc; 2024 Mar; 56(2):434-439. PubMed ID: 38355369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
    Humar A; Siegal D; Moussa G; Kumar D
    J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of leflunomide in a cytomegalovirus infection resistant: a report of a case].
    Gómez Valbuena I; Alioto D; Serrano Garrote O; Ferrari Piquero JM
    Farm Hosp; 2016 Jan; 40(1):52-4. PubMed ID: 26882834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
    Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
    BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Analysis of Ganciclovir-Resistant Cytomegalovirus in Renal Transplant Recipients with High Viral Load.
    Sohrabi M; Behzadian F; Hosseini SM; Lashini H
    Arch Iran Med; 2016 Oct; 19(10):700-703. PubMed ID: 27743434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
    Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
    Verkaik NJ; Hoek RA; van Bergeijk H; van Hal PT; Schipper ME; Pas SD; Beersma MF; Boucher CA; Jedema I; Falkenburg F; Hoogsteden HC; van den Blink B; Murk JL
    Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
    Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
    Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.
    Cvetković RS; Wellington K
    Drugs; 2005; 65(6):859-78. PubMed ID: 15819597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Fisher CE; Knudsen JL; Lease ED; Jerome KR; Rakita RM; Boeckh M; Limaye AP
    Clin Infect Dis; 2017 Jul; 65(1):57-63. PubMed ID: 28369203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small bowel transplantation complicated by cytomegalovirus tissue invasive disease without viremia.
    Avsar Y; Cicinnati VR; Kabar I; Wolters H; Anthoni C; Schmidt HH; Beckebaum S
    J Clin Virol; 2014 Jun; 60(2):177-80. PubMed ID: 24703746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
    Asberg A; Rollag H; Hartmann A
    Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial.
    Åsberg A; Humar A; Rollag H; Jardine AG; Kumar D; Aukrust P; Ueland T; Bignamini AA; Hartmann A
    Clin Infect Dis; 2016 May; 62(9):1154-60. PubMed ID: 26908810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-organ failure with fatal outcome: a case report.
    Miszewska-Szyszkowska D; Mikołajczyk N; Komuda-Leszek E; Wieczorek-Godlewska R; Świder R; Dęborska-Materkowska D; Szmidt J; Durlik M
    Ann Transplant; 2015 Mar; 20():169-74. PubMed ID: 25813912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G; Boucher HW
    Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.